Photo courtesy of ChemGenex Therapeutics
Dennis Brown left an assistant professorship at Harvard's Joint Center for Radiation in 1988 to start Matrix Pharmaceuticals. When that company sold, Brown's inner entrepreneur led him to create ChemGenex in 1999. The company works with small-molecule therapies and has two in Phase I and II clinical trials for cancer. "The first company did what it set out to do," Brown says. "Many people got significant training and went on to start their own companies."
Photo courtesy of Postimees/Scanpix Blatics
Neurobiologist Kalev Kask left AGY Therapeutics in 2001 to create EGeen, a pharmacogenetics company based in the United States and Estonia. As yet, Kask has no clear product line, but the cancer entrepreneur expects that his 25-year exclusive license for all information gleaned from the Estonian Genome Project will produce important drug therapies based on genomics and proteomics data. "The ...
